Global HIV Drugs Market to Reach $44.5 Billion by 2030
The global market for HIV Drugs estimated at US$29.6 Billion in the year 2022, is projected to reach a revised size of US$44.5 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2022-2030. Combination HIV Medicines, one of the segments analyzed in the report, is projected to record a 5.2% CAGR and reach US$29 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Integrase Inhibitors (INIs) segment is readjusted to a revised 5.7% CAGR for the next 8-year period.The U.S. Market is Estimated at $8.1 Billion, While China is Forecast to Grow at 8.8% CAGR
The HIV Drugs market in the U.S. is estimated at US$8.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$9.7 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 4.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.1 Billion by the year 2030.Select Competitors (Total 52 Featured) -
- AbbVie, Inc.
- AstraZeneca PLC
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Cipla Ltd.
- Daiichi Sankyo Co., Ltd.
- Emcure Pharmaceuticals Pvt., Ltd.
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- Hetero Drugs Ltd.
- Johnson & Johnson
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- ViiV Healthcare
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie, Inc.
- AstraZeneca PLC
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Cipla Ltd.
- Daiichi Sankyo Co., Ltd.
- Emcure Pharmaceuticals Pvt., Ltd.
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- Hetero Drugs Ltd.
- Johnson & Johnson
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- ViiV Healthcare
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 164 |
Published | May 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 29.6 Billion |
Forecasted Market Value ( USD | $ 44.5 Billion |
Compound Annual Growth Rate | 5.2% |
Regions Covered | Global |